Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
116.00 USD | +1.64% | +3.96% | +84.71% |
10/09 | Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree... | |
10/09 | Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating | MT |
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Cost of Goods Sold, Total | - | - | - | 2.3Cr | 7.5Cr | ||
Gross Profit | - | - | - | -2.3Cr | -7.5Cr | ||
Selling General & Admin Expenses, Total | 85.46L | 1.6Cr | 2.53Cr | 3.98Cr | 6.07Cr | ||
R&D Expenses | 4.56Cr | 7.36Cr | 7.84Cr | 17Cr | 33Cr | ||
Other Operating Expenses, Total | 5.42Cr | 8.96Cr | 10Cr | 21Cr | 39Cr | ||
Operating Income | -5.42Cr | -8.96Cr | -10Cr | -23Cr | -47Cr | ||
Interest Expense, Total | -40T | -7T | -7T | -2T | - | ||
Interest And Investment Income | 6L | 2L | 3L | 83.56L | 6.29Cr | ||
Net Interest Expenses | 6L | 2L | 3L | 83.54L | 6.29Cr | ||
Currency Exchange Gains (Loss) | -1L | -23.51L | 16.69L | -14.7L | -18.97L | ||
Other Non Operating Income (Expenses) | 2L | 24.78L | 15.85L | 19.31L | 47.65L | ||
EBT, Excl. Unusual Items | -5.35Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Gain (Loss) On Sale Of Investments | - | - | 2T | - | - | ||
Gain (Loss) On Sale Of Assets | - | - | - | -44T | - | ||
Legal Settlements | - | - | - | - | - | ||
Other Unusual Items | 31.85L | - | - | - | - | ||
EBT, Incl. Unusual Items | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Earnings From Continuing Operations | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Net Income to Company | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Net Income - (IS) | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Net Income to Common Incl Extra Items | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Net Income to Common Excl. Extra Items | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Per Share Items | |||||||
Net EPS - Basic | -13.25 | -3.02 | -1.93 | -3.44 | -4.14 | ||
Basic EPS - Continuing Operations | -13.25 | -3.02 | -1.93 | -3.44 | -4.14 | ||
Basic Weighted Average Shares Outstanding | 37.95L | 2.95Cr | 5.19Cr | 6.49Cr | 9.72Cr | ||
Net EPS - Diluted | -13.25 | -3.02 | -1.93 | -3.44 | -4.14 | ||
Diluted EPS - Continuing Operations | -13.25 | -3.02 | -1.93 | -3.44 | -4.14 | ||
Diluted Weighted Average Shares Outstanding | 37.95L | 2.95Cr | 5.19Cr | 6.49Cr | 9.72Cr | ||
Normalized Basic EPS | -8.8 | -1.89 | -1.2 | -2.15 | -2.59 | ||
Normalized Diluted EPS | -8.8 | -1.89 | -1.2 | -2.15 | -2.59 | ||
Supplemental Items | |||||||
EBITDA | -5.29Cr | -8.82Cr | -10Cr | -23Cr | -46Cr | ||
EBITA | -5.42Cr | -8.96Cr | -10Cr | -23Cr | -47Cr | ||
EBIT | -5.42Cr | -8.96Cr | -10Cr | -23Cr | -47Cr | ||
EBITDAR | -5.23Cr | -8.75Cr | -9.87Cr | -22Cr | -46Cr | ||
Normalized Net Income | -3.34Cr | -5.58Cr | -6.25Cr | -14Cr | -25Cr | ||
Interest on Long-Term Debt | 40T | 7T | 7T | 2T | - | ||
Supplemental Operating Expense Items | |||||||
General and Administrative Expenses | 85.46L | 1.6Cr | 2.53Cr | 3.98Cr | 6.07Cr | ||
Research And Development Expense From Footnotes | 4.56Cr | 7.36Cr | 7.84Cr | 17Cr | 33Cr | ||
Net Rental Expense, Total | 6L | 7L | 32L | 79L | 85L | ||
Imputed Operating Lease Interest Expense | 1L | - | - | 7.27T | - | ||
Imputed Operating Lease Depreciation | 5L | - | - | 78.93L | - | ||
Stock-Based Comp., R&D Exp. (Total) | 4L | 18.61L | 39.54L | 98.99L | 2.33Cr | ||
Stock-Based Comp., G&A Exp. (Total) | 8L | 35.73L | 67.75L | 1.38Cr | 2.55Cr | ||
Total Stock-Based Compensation | 11.85L | 54.34L | 1.07Cr | 2.36Cr | 4.88Cr |
- Stock Market
- Equities
- PCVX Stock
- Financials Vaxcyte, Inc.
- Income Statement